Phase 1 trials advance promising new immunotherapies for cancer
July 26, 2018
Phase 1 studies are the springboard for advancing new cancer treatments. The Earle A. Chiles Research Institute, a division of Providence Cancer Institute in the Robert W. Franz Cancer Center, is often able to offer patients first-in-human clinical trials of immunotherapies and other novel cancer therapies through our own investigator-sponsored trials, and through collaborations with partners across the country.
Here are two examples of the many phase 1 studies that we currently offer:
A Phase Ib Study of a Monoclonal Antibody to OX40 (MEDI0562) Administered Prior to Definitive Surgical Resection in Patients with Head and Neck Squamous Cell Carcinoma or Melanoma
OX40 is a cancer-fighting protein found on the surface of certain T cells. Providence researchers have engineered an antibody to the protein, called anti-OX40, which spurs T cells to destroy cancer cells. This phase 1b study builds on the promising results of a recently completed trial, which found that anti-OX40 enhanced immunity in some head and neck cancers. Offered only at Providence Cancer Institute, this newly opened trial will evaluate the safety and feasibility of anti-OX40 pre-operatively for patients with head and neck cancers or melanoma. Read more about Anti-OX40.
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
INCAGN01876 is an antibody that binds to the GITR protein on several types of T cells to activate them to find and destroy cancer cells. This study is currently enrolling patients with PD-1 or PD-L1 relapsed metastatic melanoma.
For more information or to enroll a patient, please call our Clinical Research office at 503-215-2614.
See more studies
Providence Cancer Institute currently offers more than 140 phase 1, 2 and 3 clinical trials. New studies are added frequently. For a complete list of all current studies, please visit our website.
An exceptional team
The phase 1 research program at the Earle A. Chiles Research Institute at Providence Cancer Institute is made up of oncology leaders, phase-1-dedicated nurses, data coordinators and lab assistants. Every person on this exceptional team is passionate about offering breakthrough therapies and the best possible treatment for our patients.